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The cytokine erythropoietin (Epo) is the principal regula-
tor of red cell numbers by controlling terminal differenti-
ation of immature erythroid progenitors into mature red
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Vienna Biocenter (VBC) ment of Epo signaling for red cell development. Embryos
lacking Epo or EpoR die around embryonic day E12.5Dr. Bohr-Gasse 7-9
1030 Vienna from failure of definitive erythropoiesis [1, 2]: although
the embryos produced apparently normal BFU-E andAustria
CFU-E progenitors, these failed to develop into mature,
hemoglobinized erythrocytes due to an enhanced rate
of cell death [3, 4]. In line with this, expression of Bcl-XL,Summary
an antiapoptotic member of the Bcl-2 gene family, was
strongly upregulated late during red cell maturation inBackground: Erythropoietin (Epo) is required for correct
an Epo-dependent fashion [5]. Epo withdrawal causedexecution of the erythroid differentiation program. Eryth-
downregulation of Bcl-XL and Bcl-2 followed by apopto-ropoiesis requires Bcl-XL , a major late target of Epo-
sis in Epo-dependent erythroid and lymphoid cell linesreceptor signaling. Mice lacking Bcl-XL die around em-
[6, 7]. This probably reflects an aberration of establishedbryonic age E12.5, forming normal erythroid progenitors
cell lines, since primary erythroid progenitors do notbut lacking functional red cells. Recently, serum-free
proliferate with Epo alone and express no Bcl-2 andculture conditions for expansion of murine red cell pro-
little Bcl-XL [5, 8]. Furthermore, Bcl-2 knockout mice dogenitors were developed, yielding cells capable of in
not exhibit an obvious erythroid phenotype [9]. Bcl-XL-vivo-like terminal differentiation into enucleated erythro-
mediated apoptosis protection, however, is required forcytes, in response to Epo/insulin. Here we address
erythroid differentiation since full [10] or conditional, he-whether Epo function during terminal maturation in-
matopoietic-specific Bcl-XL knockout mice [11] diedvolves a cytokine-independent “default program,” re-
during embryogenesis from fetal liver hematopoietic de-quiring only apoptosis inhibition through Epo-depen-
fects or displayed severe anemia.dent upregulation of Bcl-XL.
These observations raised the question whether EpoResults: Exogenous expression of Bcl-XL or Bcl-2 in
regulates erythroid differentiation solely through apo-primary murine erythroblasts or clonal erythroblast lines
ptosis protection via upregulation of Bcl-XL or whetherderived from p53/ mice allowed these cells to undergo
additional Epo-dependent target genes are required.terminal erythroid maturation, in the complete absence
The available, established erythroid cell lines were un-of cytokines. A potential autocrine Epo loop was ruled
suitable to address this question, since they requireout by respective neutralizing antibodies. Importantly,
nonphysiological stimuli to induce maturation and differ-sustained proliferation of Bcl-XL-expressing immature
entiate incompletely. Even when Epo-responsive forerythroblasts still required respective factors (Epo, stem
proliferation, such cell lines show aberrant patterns ofcell factor [SCF], and the glucocorticoid receptor ligand
gene expression during maturation [6, 12, 13].dexamethasone [Dex]). Epo-independent differentiation
Recently, we developed culture conditions for mousein these Bcl-XL- or Bcl-2-expressing, primary erythro-
erythroblasts allowing sustained proliferation withoutblasts was thus triggered by removal of the renewal
differentiation ( renewal) in serum-free media. Thesefactors SCF and Dex. This initiated the maturation-spe-
cells undergo terminal differentiation into enucleatedcific expression cascade of erythroid transcription fac-
erythrocytes in response to the physiological agentstors, followed by differentiation divisions (characterized
Epo and Ins [8, 14]. Characterisation of these cells byby a short G1 phase and decrease in cell size), hemoglo-
expression profiling using cDNA arrays [8] correctlybin accumulation, and enucleation.
identified genes known to be induced by Epo duringConclusions: During erythroid maturation, Epo regu-
differentiation, such as pim-1 [15] and bcl-Xl [5].lates red cell numbers via apoptosis inhibition, caused
In this paper, we demonstrate that Bcl-XL is hardlyby Epo-dependent upregulation of the antiapoptotic
expressed in renewing primary erythroblasts but isprotein Bcl-XL. This allows “default” terminal differentia-
strongly upregulated in maturing cells in a strictly Epo-tion of apoptosis-protected, committed erythroblasts,
dependent manner. Retroviral transduction of bcl-XL orindependent of any exogenous signals.
bcl-2 into primary or immortalized (p53/) erythroid pro-
genitors did not alter their dependence on renewal fac-
3 Correspondence: em@mol.univie.ac.at (E.W.M.), beug@nt.imp. tors such as Epo, stem cell factor (SCF), and dexametha-
univie.ac.at (H.B.) sone (Dex) during sustained proliferation but allowed the4 These authors contributed equally to this work.
cells to undergo terminal erythropoiesis in the complete5 These senior authors contributed equally to this work.
absence of Epo/Ins. This included differentiation divi-6 Present address: Max Planck Institute for Molecular Cell Biology
and Genetics, Pfotenhauerstrasse 108, 01307 Dresden, Germany. sions as well as induction of the characteristic expres-
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Figure 1. Bcl-XL Expression during Terminal
Erythroid Differentiation Is Induced by Epo
(A) p53/ mouse erythroblasts (clone I/11)
were induced to differentiate in standard dif-
ferentiation medium plus Epo/Ins and cyto-
spins prepared at 24 hr intervals. Black
arrows, immature erythroblasts; gray arrow-
heads, hemoglobinized (brownish stain), par-
tially mature nucleated erythroid cells; black
arrowheads, mature, enucleated erythro-
cytes; white arrowheads, extruded nuclei.
(B) Aliquots from differentiating I/11 cells
were analyzed for Bcl-XL mRNA (left; 18S: 18S
ribosomal RNA, loading control) and protein
(right; total cell lysates, using a mouse-spe-
cific Bcl-XL antibody).
(C) Cultures of I/11 cells were differentiated
in the presence (Epo) or absence (Epo) of
Epo and aliquots analyzed for Bcl-XL mRNA
(left) and protein (right) as above. Cells Epo
after 72 hr could not be analyzed, due to mas-
sive apoptosis. Bcl-XL protein appears as a
double band due to phosphorylation, which
was not always resolved due to different gel
systems; compare (B) and (C).
sion cascade of key erythroid transcription factors. Ery- tion but was strongly induced between 24 and 36 hr of
differentiation, remaining nearly constant until the endthroid progenitors protected from apoptosis by exog-
enous Bcl-XL or Bcl-2 executed the erythroid differentia- of the process at 72 hr (Figure 1B, right panel). Expres-
sion of Bcl-2 protein could neither be detected in proliferat-tion program even in the complete absence of any exog-
enous signals, as shown by using fully defined media. ing nor in differentiating erythroid cells (Figure 5B).
Previous work on erythroid cell lines dependent onThis indicates that Epo controls erythroid differentiation
via Bcl-XL-mediated apoptosis protection. In the pres- Epo for proliferation had indicated that signaling via the
EpoR caused induction of Bcl-XL, protecting proliferat-ence of Bcl-XL or Bcl-2, terminal erythroid maturation
proceeds as a cell-autonomous process, triggered by ing cells from apoptosis [7, 16, 17]. We therefore ad-
dressed in our model system whether EpoR signalingremoval of renewal factors, which seem to repress this
intrinsic default pathway in committed erythroblasts. was required for induction of Bcl-XL during terminal
erythropoiesis. I/11 erythroblasts were induced to differ-
entiate in the presence or absence of Epo and analyzedResults
at different time points for differentiation parameters as
well as for expression of bcl-XL mRNA and protein. AsEpo-Dependent Expression of Bcl-XL during
expected, erythroid cells started to undergo massiveSynchronous Red Cell Maturation
apoptosis after 48 hr of culture in the absence of EpoRecently, we described cultures of immortalized eryth-
(data not shown) and failed to express Bcl-XL at any timeroblasts from p53-deficient mice (clone I/11), which
(Figure 1C) but differentiated normally in the presence ofclosely resemble primary erythroid progenitors with re-
Epo and expressed high amounts of bcl-XL mRNA andspect to renewal factor dependence and normal ery-
protein after 48 hr (Figure 1C). In conclusion, Epo isthroid differentiation [8, 14]. We screened for potential
required for the induction of Bcl-XL late during erythroidEpo target genes by expression profiling [8] during syn-
differentiation, in line with its role in protection againstchronous, terminal erythroid maturation of these cells
apoptosis.(Figure 1A).
Of all the apoptotic and antiapoptotic genes repre-
sented on the cDNA arrays, the most striking regulation Exogenous Expression of Bcl-XL Rescues
Differentiation of Erythroid Cellswas exhibited by bcl-XL, a member of the bcl-2 gene
family with antiapoptotic function. Bcl-XL mRNA levels in the Absence of Epo
Next we analyzed whether expression of exogenousremained low during the first 20 hr of erythroid differenti-
ation but were strongly upregulated in the maturing cells Bcl-XL could substitute for Epo signaling during ery-
throid differentiation. For this, I/11 erythroblasts wereafter 48 hr, a finding confirmed by Northern blot analysis
(Figures 1A and 1B) and previously observed in other infected with a retroviral vector expressing human Bcl-
XL, linked to a GFP gene via an internal ribosome entrysystems [5, 16]. Western blot analysis confirmed that self-
renewing erythroblasts had low Bcl-XL protein expression, site (MSCV-GFP-IRES-Bcl-XL, see Experimental Proce-
dures). FACS analysis revealed that 80% of the cellswhich did not change during the first 24 hr of differentia-
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Figure 2. Erythroblasts Overexpressing Exogenous Bcl-XL Differentiate Normally in the Absence of Epo
(A) I/11 erythroblasts infected with a retrovirus expressing human bcl-XL cDNA (I/11-Bcl-XL) or empty vector (I/11-GFP) were analyzed for
bcl-XL mRNA 3, 6, and 9 days after infection (left) and for Bcl-XL protein before (prol) or after differentiation induction (diff) for 48 hr (right).
Loading control, Iron Regulatory Protein 1 (IRP-1) constitutively expressed during differentiation (E.W.M., unpublished data).
(B) I/11-Bcl-XL and I/11-GFP control cells were cytocentrifuged before (proliferation) or after differentiation for 72 hr in standard differentiation
medium /Epo.
(C) Bcl-XL-expressing and I/11-GFP erythroblasts induced to differentiate as described in (B) were analyzed for apoptosis at the times indicated
by TUNEL staining and flow cytometry (see Experimental Procedures).
(D) Quantitation of hemoglobin accumulation in the cell populations in (B) (see Experimental Procedures).
(E) Cells from the same cultures as in (B)–(D) were counted and cumulative cell numbers calculated (see Experimental Procedures).
were stably infected, thus, no sorting was required, and Another important feature of normal erythroblast dif-
all experiments were performed with infected mass cul- ferentiation is that the cells undergo three to four “differ-
tures [18]. As shown in Figure 2A, exogenous bcl-XL entiation divisions,” causing a 10- to 20-fold increase
mRNA as well as protein was stably expressed at high in cell number during maturation. These divisions are
levels (Figure 2A, left panel). Bcl-XL expression did not characterized by a shortened G1 phase and rapid size
alter the dependence of renewing cells on proliferation decrease [14, 19]. Interestingly, in the absence of Epo,
factors (Epo/SCF/Dex). In the absence of these factors, I/11-Bcl-XL cell numbers still increased 10-fold, while
Bcl-XL-overexpressing erythroblasts ceased to prolifer- I/11-GFP control cells rapidly died and disintegrated
ate within 24 hr but underwent cell death only after 6–8 (Figure 2E). Taken together, erythroid progenitors pro-
days, while control cells died within 24–48 hr (data not tected from apoptosis by exogenous Bcl-XL apparently
shown). undergo normal erythroid maturation in the absence of
We then induced the Bcl-XL-expressing I/11 erythro- Epo, including three differentiation divisions, in vivo-like
blasts (I/11-Bcl-XL) to differentiate in the presence or hemoglobin accumulation, size decrease, and enucle-
absence of Epo, compared to empty vector control cells ation (see Discussion).
(I/11-GFP). With Epo, I/11-Bcl-XL erythroblasts and I/11-
GFP control cells showed no detectable differences in
Epo-Independent Execution of the Erythroid-multiple differentiation parameters (e.g., morphology,
Specific Transcriptional Programamounts of hemoglobin, and proliferation rate; Figures
As judged from the differentiation parameters described2B–2E). Without Epo, however, control cells underwent
above, Epo was not required for erythroid differentiationnuclear fragmentation and died (Figure 2B), while Bcl-
in Bcl-XL-overexpressing erythroblasts. Therefore, weXL-expressing cells terminally differentiated into erythro-
asked whether Epo was still required to trigger the latecytes, as seen by size reduction, nuclear condensation,
erythroid transcriptional program, involving upregula-enucleation at the end of differentiation, and massive
tion of erythroid-specific transcription factors (Gata-1,accumulation of hemoglobin (Figures 2B–2E). TUNEL
EKLF, and NF-E2). Alternatively, simple removal of re-assays confirmed that I/11-Bcl-XL cells showed almost
newal factors (SCF, Dex) could trigger this program.no apoptosis without Epo (apoptotic index, 3%–10%;
I/11-Bcl-XL and I/11-GFP cells were induced to differen-Figure 2C), while I/11-GFP control cells exhibited the
tiate in the presence or absence of Epo. Total RNAexpected, high rates of apoptosis in the absence of Epo
(50% after 72 hr of differentiation). from these cells was hybridized on Northern blots, using
Bcl-XL Enables a Default Erythropoiesis Program
1079
when repression events, such as maintenance of re-
newal by c-Kit/GR signaling, are abrogated (see Dis-
cussion).
Terminal Red Cell Differentiation of Bcl-XL-
Expressing Erythroblasts Does Not
Require Any Exogenous Signals
The data presented so far did not rule out that medium
components (in serum or serum supplements) or Epo
produced in an autocrine fashion (shown to occur in
various erythroid cell lines) [22–24] might substitute for
exogenously added Epo in differentiating I/11-Bcl-XL
cells. To exclude such an autocrine Epo-loop, saturating
doses of Epo-neutralizing antibody were added to cul-
tures of I/11-Bcl-XL cells differentiating in serum-con-
taining differentiation medium. Maturation was similarly
efficient in the absence of Epo plus Epo-neutralizing
antibody as in cells plus or minus Epo (Figure 4A, left
part). Also other differentiation parameters, e.g., reduc-
tion of cell size and formation of erythrocytes (as judged
by cytospin analysis) remained unaffected (data not
shown). The same neutralizing antibody prevented dif-
ferentiation of parental I/11 cells at reduced Epo concen-
trations (Figure 4A, right panel), causing cell death in-
stead (data not shown) and inhibited Epo-dependent
proliferation of I/11 cells [14].
These results still did not exclude that (a) factor(s)Figure 3. Expression Kinetics of Erythroid Transcription Factors
from fetal calf serum or the serum supplement indis-and Epo Target Genes
pensable for renewal of immature erythroblasts mightI/11-Bcl-XL and I/11-GFP control cells were differentiated for 24–48
substitute for Epo in I/11-Bcl-XL cells. In addition, insulin,hr in standard differentiation medium /Epo. Total mRNA from
these cells as well as from proliferating controls (0 hr differentiation) which at least in chicken cooperates with Epo in sus-
was then subjected to Northern blot analysis. Blots were hybridized taining erythroid differentiation [19], was present in all
with cDNA probes specific for the Epo target genes CIS, PIM-1, and differentiation assays. To exclude such effects from Ins
bcl-XL (the latter to show endogenous versus exogenous bcl-XL and/or other, nondisclosed proteinaceous componentsmRNA expression), as well as with cDNA probes for the erythroid
present in complete StemPro34 medium, we inducedtranscription factors NF-E2, Gata-1, and EKLF; 18S ribosomal RNA,
erythroid differentiation in the “basal” StemPro mediumloading control (bottom). To demonstrate that exogenous bcl-XL
overexpression did not affect regulation of endogenous Bcl-XL pro- plus human transferrin and 99% pure bovine serum
tein, aliquots from the cell populations used for Northern blot analy- albumin. This medium permitted terminal, strictly Epo-
sis were subjected to Western blot analysis, using an antibody for dependent erythroid differentiation of I/11 erythroblasts
murine Bcl-XL (-Bcl-XL, top). similar to control medium plus serum, yielding the same
hemoglobin levels and only slightly lower numbers of
mature, partially enucleated cells (data not shown). Ery-cDNA probes for different transcription factors. The ex-
throid differentiation of I/11-Bcl-XL cells in this medium,pression levels and kinetics of early (Gata-1, EKLF) as
withdrawing Epo, Ins, or both, showed that maturationwell as late upregulated transcription factors (NF-E2;
proceeded similarly well under all conditions tested, as[8]) were identical between I/11-Bcl-XL and I/11-GFP analyzed by hemoglobin accumulation (Figure 4A),control cells, regardless of Epo administration (Figure 3).
erythrocyte numbers (Figure 4B), and decrease in cellIn contrast, bona fide target genes of Epo-induced
size (data not shown).Stat5 signaling, such as CIS and pim-1 [15, 20], were
induced in a strictly Epo-dependent fashion, irrespec-
tive of the presence or absence of exogenous Bcl-XL Bcl-XL Prevents Apoptosis but Does Not
Substitute for Proliferation Factors(Figure 3). Similarly, Epo still induced endogenous Bcl-XL
protein in both cell types during differentiation, regard- in Immature Erythroblasts Undergoing Renewal
For sustained proliferation, I/11 erythroblasts requireless of the presence or absence of exogenous Bcl-XL
(Figure 3, -Bcl-XL). Epo, SCF, and Dex [14]. In addition, they either need
serum or the “nutrient supplement” of serum-free me-In conclusion, Epo mainly controls survival of differ-
entiating erythroid cells, which execute an autonomous, dium (Stem Pro34TM) and stop to proliferate if exposed
to basal Stem Pro34TM alone. As described above, how-Epo-independent default program, including transcrip-
tional and developmental changes. Thus, Epo most ever, the latter medium plus ultra-pure BSA permitted
I/11-Bcl-XL erythroblast maturation, including two tolikely does not directly cause the early/late switch in
gene transcription which accompanies and probably three differentiation divisions [19] in the complete ab-
sence of cytokines. We therefore analyzed the behaviorspecifies the erythroid differentiation program [21].
Rather, this cell-autonomous process may be triggered of immature, proliferating cells in this defined medium.
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Figure 4. Normal Differentiation of Erythroblasts Expressing Retrovirally Transduced bcl-XL Requires No Exogenous Factors
(A) Left: I/11-Bcl-XL erythroblasts were induced to differentiate either in standard differentiation medium (serum) /Epo or the latter plus a
saturating dose of a neutralizing Epo antibody (nAB; 1.50 dilution) (left four data sets) or in fully defined differentiation medium (BSA) /Epo
and/or Ins (right four data sets). Shown are the mean values and standard deviations of hemoglobin determinations from three independent
experiments at 0, 24, 48, and 72 hr of differentiation. Right: To confirm efficient action of the Epo-neutralizing antibody, uninfected I/11 cells
were differentiated in standard medium at reduced Epo concentrations (1 U/ml) / antibody and analyzed for hemoglobin accumulation
after 72 hr.
(B) Increase in cell numbers during differentiation of I/11-Bcl-XL erythroblasts, performed in defined medium (BSA) /Epo and compared
to proliferation of the same cells under optimum conditions (standard differentiation medium Epo (serumEpo). I/11-GFP controls did not
proliferate at all in defined medium Epo.
(C) I/11-Bcl-XL and I/11-GFP control cells cultivated in standard StemPro34 plus renewal factors (N, EpoSCFDex), fully defined medium
plus the same factors (BSA, SCFEpoDex), or the same medium lacking Epo and SCF (BSA, SCFEpoDex). Proliferation kinetics
were determined by daily counting and calculation of cumulative cell numbers.
(D) Hemoglobin levels of I/11-Bcl-XL cells used in (C) were measured during the first 4 days of culture. As a positive control, hemoglobin
accumulation during standard differentiation of I/11-Bcl-XL is shown at the right.
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As expected, I/11 control cells rapidly died when kept in defined medium lacking cytokines was only marginally
less efficient than maturation of control WT-GFP eryth-in Dex alone ( absence of Epo and SCF). In the pres-
roblasts under optimal conditions (serum-containingence of renewal factors, they continued to proliferate at
medium plus Epo).a clearly reduced rate (Figure 4C), indicating the require-
In addition, WT-GFP and WT-Bcl-XL erythroblastsment of additional, unknown components for maximal
were analyzed for CFU-E colony formation in presenceproliferation. More interestingly, the Bcl-XL-expressing
and absence of Epo (Figure 5B). With Epo, both cellI/11 erythroblasts maintained in this medium plus Epo/
types gave rise to CFU-E colonies of comparable sizeSCF/Dex proliferated almost as fast as control cells (Fig-
and with the same frequency. In the absence of Epo,ure 4C) and survived as stationary, cell cycle-arrested
WT-GFP cells did not form colonies at all, whereas WT-cells for up to 7 days if deprived of Epo/SCF but not
Bcl-XL cells yielded slightly reduced numbers of smallerDex. These cells were able to resume proliferation after
colonies. Cytospin preparations indicated that the colo-readdition of Epo/SCF and did not initiate differentiation,
nies consisted of mature erythroid cells, except for WT-as depicted by constantly low hemoglobin levels, which
GFP cells cultivated without Epo, where only dead cellswere the same as in cells proliferating under full factors
could be detected.(Figure 4D). These results demonstrated that forced ex-
pression of Bcl-XL does not abolish the dependence
Exogenous Bcl-2 Can Substitute for Bcl-XLof erythroid progenitors on Epo/SCF/Dex for “renewal
in Apoptosis Protectiondivisions,” while in the same cells differentiation divi-
during Differentiationsions can proceed cell-autonomously, in the complete
Finally, we asked if other Bcl family antiapoptotic pro-absence of cytokines.
teins such as Bcl-2 would play a role during erythroid
differentiation. Neither primary nor I/11 cells expressed
endogenous Bcl-2 during proliferation or differentiation.Primary, Bcl-XL-Expressing Wild-Type
In contrast, Friend murine leukemia virus transformedErythroblasts Execute the Same Default
erythroblasts used as a positive control showed a clearErythroid Differentiation Program
Bcl-2 signal (Figure 5C, top) [25]. To test whether exoge-as Respective, Immortal p53/ Cells
nous Bcl-2 could replace Bcl-XL in allowing cytokine-Despite the close similarity of I/11 cells to primary wild-
independent differentiation, primary erythroblasts weretype erythroblasts [8, 14], we could not exclude that
infected with a retroviral construct harboring humanthe lack of p53 in combination with constitutive Bcl-XL
bcl-2 cDNA (pMSCV-Bcl-2-IRES-GFP). As expected, theexpression might be sufficient to trigger autonomous,
resulting WT-Bcl-2 cells expressed high levels of exoge-factor-independent erythroid differentiation. To address
nous Bcl-2 under all conditions tested (Figure 5C, topthis question, we established serum-free culture condi-
right). When the cells were induced for differentiation,tions allowing medium-term (about 20 days) expansion
they behaved virtually indistinguishable from their(about 105-fold) of primary, fetal liver-derived erythro-
pMSCV-Bcl-XL counterparts: efficient maturation wasblasts (E.M.D. and H.D., submitted). Using these cells,
observed in the absence of Epo (Figure 5C, bottom).
we analyzed whether primary, wild-type erythroblasts
expressing exogenous Bcl-XL also would undergo fac- Discussion
tor-independent, cell-autonomous erythroid differenti-
ation. In this paper, erythroid progenitors faithfully recapitulat-
Introduction of the Bcl-XL gene into wild-type cells ing all major in vivo steps of terminal erythroid matura-
was performed by using the same MSCV-based retrovi- tion were used to address an unsolved question: does
ral vector previously used for infection of I/11 cells. This Epo regulate erythroid cell numbers by controlling sur-
construct yielded reproducible infection rates of more vival of differentiating erythroid progenitors (which then
than 80% (data not shown; see [18]). In serum-con- mature in the absence of additional, exogenous signals),
taining medium plus Epo, batch cultures of primary wild- or does it trigger both erythroblast differentiation and
type (WT) erythroblasts expressing either GFP alone protection from apoptosis by regulating the expression
(WT-GFP) or Bcl-XL (WT-Bcl-XL) could both be success- of multiple downstream target genes (like Gata-1, CIS,
fully differentiated into enucleating erythrocytes (Figure pim-1, or bcl-XL)? By ectopic expression of a single
5A, left panels). In defined medium (basal StemPro34 target gene of Epo-dependent signaling, the antiapo-
medium plus ultra-pure BSA, see above) plus Epo, a ptotic protein Bcl-XL, in both immortalized p53/ and
similarly complete maturation of both cell types could primary wild-type erythroblasts, we provide strong evi-
be obtained (data not shown). In defined medium lacking dence for the first alternative: the antiapoptotic effect
Epo/Ins, however, only WT-Bcl-XL cells were able to of Epo-induced Bcl-XL upregulation alone was sufficient
accumulate hemoglobin and undergo complete matura- to allow cell-autonomous execution of the terminal
tion (Figure 5A, bottom right). As expected, WT-GFP erythropoiesis program, including sequential expres-
control cells died under these conditions (Figure 5A, top sion of erythroid-specific transcription factors. This also
right). These results were confirmed (1) by quantitative suggests that no other known Epo target genes are
evaluation of cytospins for enucleated erythrocytes, nu- essential for this maturation process.
cleated maturing cells, and dead cells (Figure 5A, pie dia-
grams below photographs); (2) by photometric hemoglo- Erythroid Differentiation—A Default,
bin determinations; and (3) by determining cell proliferation Intrinsic Pathway
during differentiation (data not shown). With respect to An important finding of this paper is that terminal ery-
throid differentiation depends on apoptosis protectionall these parameters, differentiation of WT-Bcl-XL cells
Current Biology
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Figure 5. Primary Fetal Liver-Derived Erythroblast Ectopically Expressing Bcl-XL or Bcl-2 Differentiate in the Absence of Factors
(A) Primary erythroblasts expressing GFP (top, WT-GFP) or GFP-Bcl-XL (bottom, WT Bcl-XL) were differentiated in standard (serum Epo) or
defined medium without Epo (defined Epo). Cytospins prepared after 48 hr of differentiation were stained and photographed or evaluated
quantitatively (pie diagrams) for enucleated erythrocytes (red), nucleated mature cells (orange), or apoptotic/disintegrated cells (black). White
arrows, apoptotic cells; gray arrowheads, hemoglobinized, partially mature erythroid cells; black arrowheads, mature, enucleated erythrocytes;
white arrowheads, extruded nuclei.
(B) Cells from (A) were seeded in CFU-E methocel /Epo and analyzed for colonies 2 days later. Top, photomicrographs; bottom, cytospin
preparations from isolated colonies.
(C) Top: Bcl-2 protein expression in I/11 cells and primary erythroblasts under proliferation or differentiation conditions /Epo, analyzed
before and after infection with pMSCV-Bcl-2-IRES-GFP or pMSCV-GFP (see Experimental Procedures). HB22, positive control for endogenous
Bcl-2, Friend-MLV-transformed erythroblasts [25]. Bottom: Primary WT-Bcl-2 or WT-GFP control erythroblasts (see top panel) were differenti-
ated as described in (A) and cytospins prepared.
by Bcl-XL, upregulated by EpoR signaling. In the ab- deprived control cells devoid of exogenous Bcl-XL. This
indicates that Epo cannot be the agent initiating thissence of Epo, bcl-XL mRNA and protein remain at basal
levels, insufficient to protect maturing cells from cell transcription factor cascade (see below).
Using a fully defined medium (containing only low MWdeath. It was, however, unclear whether EpoR signaling
would also trigger the erythroid differentiation program, chemicals plus ultra-pure BSA and iron-loaded trans-
ferrin), we also demonstrated that Bcl-XL-expressingi.e., initiate activation of early and late erythroid-specific
transcription factors. Our results clearly indicate that cells required no other exogenous factor (e.g., substitut-
ing for Epo/Ins) to complete execution of the erythroidboth p53/ and primary, wild-type erythroblasts could
undergo a cell-autonomous, default differentiation pro- differentiation program. With an Epo-neutralizing anti-
body, we could exclude an Epo autocrine loop [23, 24]gram if protected from apoptosis by expression of exog-
enous Bcl-XL or Bcl-2. Cytokine-independent, terminal as a reason for factor-independent differentiation. This
identifies Bcl-XL as the Epo-target gene both essentialerythropoiesis of Bcl-XL-expressing cells was indistin-
guishable from the Epo-induced maturation of control and sufficient for erythroid maturation.
Our findings contrast previous observations that ret-cells with respect to multiple differentiation parameters.
Importantly, the expression pattern of erythroid-spe- rovirally mediated expression of Bcl-XL (or Bcl-2) in iso-
lated erythroid progenitors could not substitute for Epocific transcription factors (Gata-1, EKLF, NF-E2) [8, 19]
was similar between Bcl-XL-expressing erythroblasts in CFU-E colony formation [26]. In this study, Bcl-XL
protein expression levels were not determined, relyingdifferentiating in the absence of cytokines and control
cells maturing under optimal conditions. Importantly, on GFP coexpression alone. Together with the fact that
our Bcl-XL-expressing primary erythroblasts readilythe earlier steps of this transcription factor cascade
(i.e., within the first 36–48 hr) were also induced in Epo- formed normal numbers of CFU-E colonies, this could
Bcl-XL Enables a Default Erythropoiesis Program
1083
mean that Bcl-XL expression was too low to allow Epo- fewer cytokines for renewal, (over)express antiapoptotic
proteins, and differentiate only partially or abnormally.independent colony formation in the above report. In
another study, erythroid progenitors from mice carrying Known or unknown oncogenes with their mutations and
amplifications (e.g., v-ErbA, v-ErbB, sea, c-Kit, or flk-2)a bcl-2 transgene were much less sensitive to reduced
Epo levels in CFU-E assays, although they did not form [30–33] provide these erythro-leukemic cells with consti-
tutive renewal signals, which cannot be turned off andcolonies in the complete absence of Epo [27]. Together
with recent findings that primary chicken erythroid pro- thus prevent triggering of terminal maturation. This may
explain why only partial differentiation occurs in suchgenitors overexpressing bcl-2 differentiated terminally
without Epo [25], we conclude that apoptosis inhibition cell lines, often combined with ongoing proliferation.
This idea is supported by oncogenic mutations inducingby bcl-2 family antiapoptotic proteins is sufficient for
terminal erythropoiesis to occur, without requirement proliferation and interfering with maturation in other he-
matopoietic lineages or even multipotent progenitorsfor additional factors. The relevant in vivo target of Epo-
signaling, however, clearly is Bcl-XL, since neither pri- [34, 35]. Importantly, the leukemia-inducing protoonco-
gene Bcl-2 or its close relative Bcl-XL did not contributemary avian nor murine erythroid progenitors express
Bcl-2. In addition, broad range caspase inhibitors or to renewal of primary erythroblasts at all, suggesting
that antiapoptotic signals by bcl family proteins requireablation of caspase-2 prevented normal erythropoiesis
in our primary cell model. Apparently, caspase activity is cooperation with other oncogenes to cause leukemia.
required for apoptosis-independent protein degradation
processes during terminal maturation (S. Pilat, A. Kol- Epo Signaling and Bcl-XL Upregulation in Erythroid
Differentiation as Analyzed in Geneticallybus, H.B., and M. Baccharini, submitted). This repre-
sents another argument for our idea that apoptosis pro- Modified Mice
The idea that bcl-XL is an essential target gene of Epotection by Bcl-XL is physiologically relevant in erythroid
differentiation. and required for erythropoiesis in vivo is strengthened
by phenotypes of mice with a disrupted bcl-XL gene.How then is maturation and upregulation of erythroid-
specific transcription factors triggered in our cell models? Constitutive elimination of bcl-XL caused death at E12.5
due to severe anemia and brain defects [10]. Mice withThe observations suggest that withdrawal of renewal
factors (SCF and Dex) initiates erythroid differentiation. a conditional disruption of bcl-XL in the hematopoietic
system were born but showed massive hemolytic ane-Based on preliminary results from expression profiling,
SCF and Dex may prevent activation of a “dormant” mia [11]. In both cases, the bcl-XL-defective animals
lacked mature erythrocytes but produced large numbersbut preexisting program required to initiate erythroid
differentiation. Interference of an active GR with terminal of immature erythroid progenitors, such as BFU-E and
CFU-E cells as well as nucleated proerythroblasts.differentiation would explain why Bcl-XL-expressing
cells undergo normal maturation in differentiation media These findings are in excellent agreement with the low
or absent bcl-XL expression in immature erythroblasts(where Dex is replaced by its antagonist ZK 112.993),
while they arrest in cell cycle without maturation in the and its late upregulation during erythrocyte formation,
as initially described by others and seen in our in vivo-defined medium lacking Epo/SCF but not GR ligands
(Figure 4C). Thus, we hypothesize that renewal factors like differentiation systems.
such as SCF and Dex cooperate with Epo to maintain
erythroblast proliferation and to repress a default ery- Conclusions
Our results establish that erythroid differentiation canthroid differentiation program, which is initiated by with-
drawal of SCF and Dex and then only requires apoptosis take place as a cell-autonomous program, including dif-
ferentiation divisions, in the absence of exogenous sig-protection by Epo-induced Bcl-XL for its completion.
nals, provided that the antiapoptotic protein Bcl-XL is
upregulated by Epo. This erythroid maturation process
Renewal Signals Preventing Cell-Autonomous requires the antiapoptotic activity of Bcl family proteins
Differentiation: A General Principle rather than Bcl-XL-specific functions. During progenitor
in Leukemia? renewal, execution of the intrinsic erythroid differentia-
The concept that renewal-inducing signals have to be tion program is suppressed by the proliferation-promot-
completely removed in order to allow triggering of the ing factors SCF and Dex and maturation is triggered by
erythroid differentiation program also applies to other their removal.
systems. Cell-autonomous differentiation was sup-
Experimental Procedurespressed by proliferation/renewal factors (PDGF and
FGF) in oligodendrocyte/astrocyte progenitors, which
Cells and Culture Conditionsundergo a fixed number of cell divisions when protected
Immortal mouse erythroblasts (clone I/11; p53 deficient [8]) were
from apoptosis by the combined action of neurotrophins maintained in serum-free medium (StemPro-34TM; Life Technologies)
and hormones [28, 29]. Thus, cell-autonomous differen- supplemented with human recombinant erythropoietin (Epo; 2 units/
ml; Erypo, Cilag AG), murine recombinant stem cell factor (SCF, 100tiation programs triggered by the removal of signals
ng/ml; R&D Systems), dexamethasone (Dex; 106 M; Sigma), andfavoring proliferation/differentiation arrest may be a
insulin-like growth factor 1 (IGF-1; 40 ng/ml; Promega) as describedmore generally applicable paradigm.
[14]. Primary erythroblasts were obtained from fetal livers of wild-Renewal factor-induced differentiation arrest may
type mice (C57/Bl-6/129 mixed) at E11.5–E13.5 as described in detail
also bear relevance for understanding the development elsewhere (E.M.D. et al., submitted) and cultivated in the same me-
of (erythro-)leukemia. Leukemic cells often differ from dium. Proerythroblast cultures were expanded by daily partial me-
dium changes and addition of fresh factors, keeping cell densitiestheir primary counterparts in that they require no or
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between 1.5 to 4 106 cells/ml. For some experiments, proliferation reaction buffer (Roche), 0.5 nM FluoroLink Cy5-dCTP (Amersham),
and 12.5 U TdT (Roche) for 1 hr at 37C. Cells were washed oncewas carried out in fully defined medium (basal StemPro34medium
lacking Nutrient supplement), containing 6.6 mg/ml highly purified with HBS and resuspended in HBS containing 10 g/ml DAPI to
determine DNA content and subjected to flow cytometry.BSA (99% pure, Sigma, #A0281) plus renewal factors (Epo, SCF,
Dex, IGF-1) and iron-saturated transferrin (300 g/ml; Roche). Cell
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